ZP1609/danegaptide and mitochondrial connexin hemichannels: a harbinger for peptide drug design

Linked Articles

This article is a Commentary on Boengler K, Bulic M, Schreckenberg R, Schlüter K‐D, Schulz R (2017). The gap junction modifier ZP1609 decreases cardiomyocyte hypercontracture following ischaemia/reperfusion independent from mitochondrial connexin 43. Br J Pharmacol 174: 2060–2073. https://doi.org/10.1111/bph.13804

DOI: 10.1111/bph.13891

View this article

• Full article (html)
• Enhanced article (html)
• PDF
• References